<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4446">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 14, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04798625</url>
  </required_header>
  <id_info>
    <org_study_id>DIA2021-1</org_study_id>
    <nct_id>NCT04798625</nct_id>
  </id_info>
  <brief_title>Vaccine Response to COVID-19 Vaccines in Patients Using Immunosuppressive Medication</brief_title>
  <acronym>Nor-vaC</acronym>
  <official_title>A Norwegian Study of Vaccine Response to COVID-19 Vaccines in Patients Using Immunosuppressive Medication Within Rheumatology and Gastroenterology: the Nor-vaC Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Diakonhjemmet Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital, Akershus</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Diakonhjemmet Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the strength and duration of the immunological&#xD;
      response to COVID-19 vaccines in patients treated with immunosuppressive and/or&#xD;
      immunomodulating medication for immune-mediated inflammatory diseases in rheumatology and&#xD;
      gastroenterology and after a liver transplantation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients on long-term immunosuppressive and/or immunomodulating medication may be susceptible&#xD;
      to serious COVID-19. Hence, it is important they get sufficient protection by a COVID-19&#xD;
      vaccine. However, these patients may also be at risk for a less robust vaccine response.&#xD;
      There is an urgent need to assess the humoral and cellular immune response to COVID-19&#xD;
      vaccines in these patient groups. The clinical consequences could be to administer several&#xD;
      re-vaccinations or to adjust medication. This prospective, observational study aims to assess&#xD;
      the immune response after COVID vaccination in patients suffering from inflammatory diseases&#xD;
      and using immunosuppressive medication. Also, liver transplanted patients on&#xD;
      immunosuppressive medication will be included.&#xD;
&#xD;
      Serum and whole blood samples will be obtained from all participants before and 1-4 weeks&#xD;
      after the vaccination. Additionally, serum samples will be collected every 3-6 months for 5&#xD;
      years. In a subset of patients, samples will be drawn to study cellular immune responses.&#xD;
      Demographic data and data regarding immunosuppressive medication will be recorded. Disease&#xD;
      activity (clinical activity indices and biomarkers of inflammation) will be assessed. Blood&#xD;
      samples will be obtained for biobank. Information regarding vaccination status and potential&#xD;
      COVID-19 testing will be obtained from relevant registers.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 15, 2021</start_date>
  <completion_date type="Anticipated">February 15, 2027</completion_date>
  <primary_completion_date type="Anticipated">February 15, 2026</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Serological response</measure>
    <time_frame>4 weeks after vaccination, then at 3 month intervals during the first year and 6 month intervals for up to a total of 5 years</time_frame>
    <description>Change from baseline in serum levels of anti-SARS-CoV-2 antibodies</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cellular response</measure>
    <time_frame>7-10 days after vaccination, then at 3 month intervals during the first year and 6 month intervals for up to a total of 5 years</time_frame>
    <description>Change from baseline in T cell reactivity to SARS-CoV-2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Reported by patient for the first 48 hours following each vaccine dose</time_frame>
    <description>Occurence of patient-reported adverse events related to vaccination against COVID-19</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BASDAI</measure>
    <time_frame>Within 4 weeks of the patient receiving the final dose of vaccine</time_frame>
    <description>BASDAI questionnaire to assess disease activity in spondyloarthritis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Partial Mayo score</measure>
    <time_frame>Every 3 months for the first year of study, every 6 months thereafter until study completion</time_frame>
    <description>Partial Mayo score to assess disease activity in ulcerative colitis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Harvey-Bradshaw index (HBI)</measure>
    <time_frame>Every 3 months for the first year of study, every 6 months thereafter until study completion</time_frame>
    <description>Harvey-Bradshaw index to assess disease activity in Crohn disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DAS28</measure>
    <time_frame>Within 4 weeks of the patient receiving the final dose of vaccine</time_frame>
    <description>Disease Activity Score 28 to assess disease activity in RA and PsA</description>
  </secondary_outcome>
  <number_of_groups>7</number_of_groups>
  <enrollment type="Anticipated">1600</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <condition>Psoriatic Arthritis</condition>
  <condition>Spondyloarthritis</condition>
  <condition>Crohn Disease</condition>
  <condition>Ulcerative Colitis</condition>
  <condition>Autoimmune Hepatitis</condition>
  <condition>Liver Transplant; Complications</condition>
  <arm_group>
    <arm_group_label>Rheumatoid arthritis</arm_group_label>
    <description>Patients with a clinical diagnosis of rheumatoid arthritis and treated with immunosuppressive medication</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Psoriatic arthritis</arm_group_label>
    <description>Patients with a clinical diagnosis of psoriatic arthritis and treated with immunosuppressive medication</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Spondyloarthritis</arm_group_label>
    <description>Patients with a clinical diagnosis of spondyloarthritis and treated with immunosuppressive medication</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Crohn disease</arm_group_label>
    <description>Patients with a clinical diagnosis of Crohn disease and treated with immunosuppressive medication</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ulcerative colitis</arm_group_label>
    <description>Patients with a clinical diagnosis of ulcerative colitis and treated with immunosuppressive medication</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Autoimmune hepatitis</arm_group_label>
    <description>Patients with a diagnosis of autoimmune hepatitis and treated with immunosuppressive medication</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Liver transplant</arm_group_label>
    <description>Patients who have undergone liver transplantation and are treated with immunosuppressive drugs</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood Serum White blood cells&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Candidate patients will be recruited from the population treated at the two study centres&#xD;
        and, if eligible, asked to participate in the observational cohort&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. An established clinical diagnosis of one of the following immune-mediated diseases:&#xD;
             rheumatoid arthritis (RA), spondyloarthritis (SpA), psoriatic arthritis (PsA),&#xD;
             ulcerative colitis (UC,) Crohns disease (CD), autoimmune hepatitis (AIH) or patients&#xD;
             who have undergone a liver transplantation&#xD;
&#xD;
          2. Treatment with relevant immunosuppressive and/or immunomodulating medication *&#xD;
&#xD;
          3. Adult patients (&gt; 18 years)&#xD;
&#xD;
          4. Patient intends to obtain vaccination against COVID-19 during the next 6 months&#xD;
&#xD;
               -  * The following drugs are considered relevant immunosuppressants and/or&#xD;
                  immunomodulators and patients using them may be eligible for this study:&#xD;
                  Rituximab, infliximab, adalimumab, golimumab, certolizumab, etanercept,&#xD;
                  tocilizumab, abatacept, secukinumab, vedolizumab, ustekinumab, risankizumab,&#xD;
                  methotrexate, sulfasalazine, leflunomide, azathioprine, 6-mercaptopurine,&#xD;
                  tofacitinib, filgotinib, baricitinib, upadacitinib, tacrolimus, mycophenolate,&#xD;
                  prednisolone&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        1) Allergy or intolerance to elements of the COVID-19 vaccines&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Guro L Goll, MD PhD</last_name>
    <phone>+47 22451500</phone>
    <email>gurolovik.goll@diakonsyk.no</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kristin K Jørgensen, MD PhD</last_name>
    <phone>+47 67960000</phone>
    <email>Kristin.Kaasen.Jorgensen@ahus.no</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Akershus University Hospital</name>
      <address>
        <city>Lørenskog</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristin K Jørgensen, MD PhD</last_name>
      <phone>+4767960000</phone>
      <email>Kristin.Kaasen.Jorgensen@ahus.no</email>
    </contact>
    <contact_backup>
      <last_name>Jørgen Jahnsen, MD PhD</last_name>
      <phone>4767960000</phone>
      <email>jorgen.jahnsen@medisin.uio.no</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Diakonhjemmet Hospital</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guro L Goll, MD PhD</last_name>
      <phone>+4722451500</phone>
      <email>gurolovik.goll@diakonsyk.no</email>
    </contact>
    <contact_backup>
      <last_name>Silje W Syversen, MD PhD</last_name>
      <phone>+47 22451500</phone>
      <email>SiljeW.Syversen@diakonsyk.no</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 10, 2021</study_first_submitted>
  <study_first_submitted_qc>March 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 15, 2021</study_first_posted>
  <last_update_submitted>March 12, 2021</last_update_submitted>
  <last_update_submitted_qc>March 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Diakonhjemmet Hospital</investigator_affiliation>
    <investigator_full_name>Guro Løvik Goll</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Psoriatic</mesh_term>
    <mesh_term>Spondylarthritis</mesh_term>
    <mesh_term>Crohn Disease</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Hepatitis, Autoimmune</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

